Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Chief Financial Officer | November 06, 2020 | November 10, 2020 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | Director | May 17, 2022 | August 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date November 06, 2020 · Filed November 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,590 |
Reported balance
After 2020-11-06 transaction · row 1
1 source rowRow 1 · 2020-11-06 · Sale · Disposed 3,827 · Balance 67,590 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019.
Rockley Photonics Holdings Ltd
Report date May 17, 2022 · Filed August 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 65,322 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 65,322 · Balance 65,322 F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 27,546 |
Ending reported balance
After 2019-04-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-01 · Disposition to issuer · Disposed 85,312 · Balance 26,063 F1: Represents the disposition of 85,312 restricted stock units in connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood") in exchange for restricted stock units representing the right to receive shares of Cyclerion Common Stock. Row 2 · 2019-04-01 · Grant · Acquired 1,483 · Balance 27,546 F2: In connection with the Separation, the reporting person received 1,483 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. This award vests as shares of Class A Common Stock on May 9, 2019. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2028-01-02 | Direct | 105,468 |
Reported balance
After 2019-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-01 · Disposition to issuer · Disposed 232,032 · Balance 105,468 F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F4: The remaining 105,468 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2029-01-29 | Direct | 16,171 |
Reported balance
After 2019-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-01 · Disposition to issuer · Disposed 242,579 · Balance 16,171 F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F5: The remaining 16,171 shares are presently exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the disposition of 85,312 restricted stock units in connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood") in exchange for restricted stock units representing the right to receive shares of Cyclerion Common Stock.
F2: In connection with the Separation, the reporting person received 1,483 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. This award vests as shares of Class A Common Stock on May 9, 2019.
F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award.
F4: The remaining 105,468 shares are presently exercisable in full.
F5: The remaining 16,171 shares are presently exercisable in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2022 Filed Aug 30, 2022 16:30 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 65,322 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000308 · wf-form4_166189141151528.xml · derivative · entry 1 Huyett William · CIK 0001723846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,322 Underlying: Ordinary Share · 65,322 shares Expires not disclosed F1 · derivative.exercise_date: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. F1 · derivative.expiration_date: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. Read SEC document |
| May 16, 2022 Filed Jun 8, 2022 18:15 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | Exercise / conversionRestricted Stock Unit · Derivative | 7,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000200 · wf-form4_165472652798767.xml · derivative · entry 2 Huyett William · CIK 0001723846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,667 Underlying: Ordinary Share · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each Restricted Stock Unit converted into one Ordinary Share effective 5/16/2022 F1 · derivative.expiration_date: Each Restricted Stock Unit converted into one Ordinary Share effective 5/16/2022 Read SEC document |
| May 16, 2022 Filed Jun 8, 2022 18:15 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | Exercise / conversionOrdinary Share | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000200 · wf-form4_165472652798767.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 19:17 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | PurchaseOrdinary Share | 25,000 | $6.59 | $164,750.00 |
DisclosureSEC source: 0001852117-21-000063 · wf-form4_163779944880590.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 15:58 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 22,000 | $7.14 Strike: $0.00 | $157,080.00 |
DisclosureSEC source: 0001852117-21-000045 · wf-form4_163475987757655.xml · derivative · entry 1 Huyett William · CIK 0001723846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Ordinary Share · 22,000 shares Expires not disclosed F1 · derivative.exercise_date: One third of the RSUs shall vest on the earlier of August 11, 2022 or the next annual shareholders' meeting, and in each of the next two calendar years following the year of the initial vesting date, an additional one third shall vest on the earlier of the 12-month anniversary of the prior annual shareholders' meeting or the current year annual shareholder' meeting, subject to acceleration upon a change in control. F1 · derivative.expiration_date: One third of the RSUs shall vest on the earlier of August 11, 2022 or the next annual shareholders' meeting, and in each of the next two calendar years following the year of the initial vesting date, an additional one third shall vest on the earlier of the 12-month anniversary of the prior annual shareholders' meeting or the current year annual shareholder' meeting, subject to acceleration upon a change in control. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 19:07 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 3,827 | $2.52 | $9,644.04 |
DisclosureSEC source: 0001209191-20-057768 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,590 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 16:11 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 3,559 | $5.12 | $18,222.08 |
DisclosureSEC source: 0001209191-20-012430 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,417 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.12 to $5.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 17:42 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-058162 · doc4.xml · derivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-11-22 F1 · derivative.exercise_date: The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021. F2 · derivative.expiration_date: To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 16:26 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 3,922 | $2.05 | $8,040.10 |
DisclosureSEC source: 0001209191-19-056008 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,976 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.05 to $2.0675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 242,579 | Not disclosed Strike: $11.49 | Not disclosed |
DisclosureSEC source: 0001209191-19-023429 · doc4.xml · derivative · entry 4 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,171 Underlying: Class A Common Stock · 242,579 shares Expires 2029-01-29 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F5 · derivative.exercise_date: The remaining 16,171 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 232,032 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-023429 · doc4.xml · derivative · entry 3 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,468 Underlying: Class A Common Stock · 232,032 shares Expires 2028-01-02 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F4 · derivative.exercise_date: The remaining 105,468 shares are presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023429 · doc4.xml · nonDerivative · entry 2 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,546 F2 · price: In connection with the Separation, the reporting person received 1,483 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. This award vests as shares of Class A Common Stock on May 9, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerClass A Common Stock | 85,312 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023429 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,063 F1 · price: Represents the disposition of 85,312 restricted stock units in connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood") in exchange for restricted stock units representing the right to receive shares of Cyclerion Common Stock. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:39 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 222,002 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0001209191-19-023517 · doc4.xml · derivative · entry 4 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,002 Underlying: Common Stock · 222,002 shares Expires 2029-01-29 F4 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:39 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 221,349 | $0.00 Strike: $16.81 | $0.00 |
DisclosureSEC source: 0001209191-19-023517 · doc4.xml · derivative · entry 3 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,349 Underlying: Common Stock · 221,349 shares Expires 2028-01-02 F4 · derivative.exercise_price: Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation. F5 · derivative.exercise_date: The option, granted as a new hire award, vested as to 25% of the shares of common stock on December 15, 2019, and 2.08333% of the shares of common stock vest each month thereafter for the next 36 months. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:39 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 39,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023517 · doc4.xml · nonDerivative · entry 2 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,912 F2 · shares: In connection with the Separation, the reporting person received a grant of 39,179 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant. F3 · balance_after: Includes 1,406 shares of Cyclerion common stock received in a pro rata distribution by Ironwood as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:39 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 38,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023517 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,327 F1 · shares: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals Inc. ("Ironwood"), the reporting person received a grant of 38,327 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 221,964 | $0.00 Strike: $14.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · derivative · entry 4 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,964 Underlying: Common Stock · 221,964 shares Expires 2029-01-29 F5 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2019. F2 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 221,312 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · derivative · entry 3 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,312 Underlying: Common Stock · 221,312 shares Expires 2028-01-02 F5 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F6 · derivative.exercise_date: The option, granted as a new hire award, vested as to 25% of the shares of common stock on December 15, 2018, and 2.08333% of the shares of common stock vest each month thereafter for the next 36 months. F2 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 39,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · nonDerivative · entry 2 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,898 F3 · shares: In connection with the Separation, the reporting person received a grant of 39,172 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant. F4 · balance_after: This report has been amended to reflect the number of shares received in a pro rata distribution as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 38,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,320 F1 · shares: In connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals Inc. ("Ironwood") effective April 1, 2019 (the "Separation"), the reporting person received a grant of 38,320 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant. F2 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 258,750 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006226 · doc4.xml · derivative · entry 2 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,750 Underlying: Class A Common Stock · 258,750 shares Expires 2029-01-29 F2 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:34 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 43,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006226 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,375 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 21:59 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045055 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,250 F1 · kind: The restricted stock unit award, granted as a recognition award, vests as to 100% of the shares of Class A Common Stock on May 9, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 337,500 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001209191-18-001576 · doc4.xml · derivative · entry 2 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,500 Underlying: Class A Common Stock · 337,500 shares Expires 2028-01-02 F2 · derivative.exercise_date: The option, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of December 15, 2017, and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 56,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001576 · doc4.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 F1 · kind: The restricted stock unit award, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.